The ASSURE study: HIV‐1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + ...

por Wohl, DA, Bhatti, L, Small, CB, Edelstein, H, Zhao, HH, Margolis, DA, DeJesus, E, Weinberg, WG, Ross, LL, Shaefer, MS
Publicado 2015

SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients

por Kumar, P, DeJesus, E, Huhn, G, Sloan, L, Garcia, F, Small, C, Edelstein, H, Felizarta, F, Hao, R, Ha, B, Stancil, B, Ross, L, Oie, K, Pappa, K
Publicado 2010